Sixty years of experience with hereditary transthyretin amyloidosis: Insights from the Swedish transthyretin amyloidosis registry
Journal of Internal Medicine · 2025
DOI: 10.1111/joim.70020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Internal Medicine, 2025. Verfasst von Lotta Stenberg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Västerbotten Läns Landsting.
Abstract (Originalsprache)
Background
Hereditary transthyretin (ATTRv) amyloidosis was first described in Sweden in the late 1960s. Selected patient data have been collected since then and have now been transferred to a national quality registry.
Methods
This is the first report from SveATTR—a longitudinal Swedish web‐based registry open for TTR variant carriers and patients with ATTR amyloidosis. The registry covers basic background information, as well as relevant clinical follow‐up measures and data on disease‐modifying therapies. Data from all ATTRv amyloidosis patients registered through December 2022 were included.
Results
In total, 1055 patients were included, of whom 65% were males and 95% carried the V30M variant. Median age of onset was 64 years, and 79% had a late disease onset (≥50 years). Eighty‐seven percent of the patients had peripheral polyneuropathy at onset, whereas 10% had cardiac symptoms, 8% had visual disturbances, and 6% had gastrointestinal symptoms. A total of 159 patients had undergone liver transplantation, and 233 had received a disease‐modifying drug. Improved survival was seen for transplanted patients and for patients on drug therapy.
Conclusion
This report highlights the importance of SveATTR for further characterization of the Swedish ATTRv amyloidosis population as well as for evaluating the efficacy of disease‐modifying therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
- Department of Medicine, Norrland's University Hospital, Umeå, Sweden.
- Department of Medicine, Piteå Hospital, Piteå, Sweden.
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
- Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.
- Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Förderung
- Västerbotten Läns Landsting
Zitieren
APA
Stenberg, L., Pilebro, B., Anan, I., Baranda, J. M., Samuelsson, K., Eldhagen, P., Backlund, R., & Wixner, J. (2025). Sixty years of experience with hereditary transthyretin amyloidosis: Insights from the Swedish transthyretin amyloidosis registry. Journal of Internal Medicine. https://doi.org/10.1111/joim.70020
Vancouver
Stenberg L, Pilebro B, Anan I, Baranda JM, Samuelsson K, Eldhagen P, et al. Sixty years of experience with hereditary transthyretin amyloidosis: Insights from the Swedish transthyretin amyloidosis registry. Journal of Internal Medicine. 2025. doi:10.1111/joim.70020
BibTeX
@article{Stenberg2025,
author = {Stenberg, Lotta and Pilebro, Björn and Anan, Intissar and Baranda, Jorge Mejia and Samuelsson, Kristin and Eldhagen, Per and Backlund, Rolf and Wixner, Jonas},
title = {Sixty years of experience with hereditary transthyretin amyloidosis: Insights from the Swedish transthyretin amyloidosis registry},
journal = {Journal of Internal Medicine},
year = {2025},
doi = {10.1111/joim.70020}
}
EUVIMED